Wall Street bounces back on Wednesday; UK approves Astrazeneca’s vaccine
|US equities moved higher on Wednesday, after retreating during the previous session. The upbeat mood prices in investors' hope that 2021 will be a much better year for the economy, which may be pushed by COVID vaccine rollouts and more stimulus.
Expectations for bigger direct payments faded after Senate Majority Leader Mitch McConnell turned down a quick vote to approve President Donald Trump's request to boost relief checks from $600 to $2,000.
Still, the massive $2.3 trillion stimulus package signed by Trump in the weekend is enough to support the bullish stance.
The Dow Jones rose 0.24% to update the record high. The S&P 500 added 0.13%, and Nasdaq rose 0.15%. Eight out of 11 S&P sectors moved higher, with energy and materials being the best performers. Trading volumes are much lower during the holidays.
The S&P 500 has gained about 15.5% year-to-date, driven by massive stimulus implemented by the government and cash injections from the Federal Reserve. In the final quarter, the rally was fueled by the vaccine news.
Nasdaq is set to record its best yearly performance in over a decade, with FAANG stocks being in the spotlight.
Investor sentiment was boosted after the UK approved the emergency use of the COVID vaccine produced by AstraZeneca and Oxford University. The first shots will be administered on Monday. Still, investors are worried about the new COVID strain first discovered in the UK. The first cases in the US have been confirmed in Colorado.
In Asia, stocks are mostly bullish during their last trading day of 2020. The optimism is supported by the UK's approval of the COVID vaccine produced by AstraZeneca and expectations of a global economic recovery in 2021.
At the time of writing, China's Shanghai Composite is up 1.30%, and the Shenzhen Component has surged 1.38%. Chinese factory activity increased at a slower pace, according to data released earlier in the day. Manufacturing PMI came in at 51.9 in December, down from November's 52.1 figure and slightly lower than forecasts. The data also showed that non-manufacturing PMI came in at 55.7 in December, also down from November's 56.4.
Hong Kong's Hang Seng Index is up 0.43%.
In Australia, the ASX 200 tumbled 1.42%.
Markets in Japan and South Korea are closed ahead of the New Year.
In the commodity market, oil prices are somewhat bearish after opening higher. The concerns over the new COVID strain offset the optimism surrounding the UK approval of AstraZeneca's vaccine. Both WTI and Brent have lost 0.10% so far. Initially, prices were boosted by data released by the Energy Information Administration (EIA), which showed a draw in crude inventories of over 6 million barrels last week. Investors expected a draw of over 2.5 million barrels. Previously, the American Petroleum Institute reported a draw of almost 4.8 million barrels. 2020 has been a tumultuous year for crude prices, which have declined about 20% since the beginning of the year. At one point, WTI futures turned negative for the first time ever, as demand tumbled. Nevertheless, unprecedented stimulus from governments worldwide helped crude prices recover part of the losses.
Gold futures have declined slightly, but are set to conclude the best year in a decade, as investors have looked for safe havens amid the COVID crisis. The metal is down 0.04% to $1,892.
In FX, the US dollar cannot find its bottom as the American currency is trading at the lowest level since April 2018. The USD Index fell 0.07% to 89.582. Still, EUR/USD is down 0.02% to 1.2292.
The British pound has gained about 0.10% against both majors after the UK approved AstraZeneca's vaccine. Also, the British parliament approved Prime Minister Boris Johnson's Brexit trade deal with the EU. Both sides want to start a new chapter in their relationship.
Stay on top of the markets with Swissquote’s News & Analysis
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.